HENGRUI PHARMA Shares Surge Over 4% in Late Trading as China's First Anti-HER2 Product for Colorectal Cancer Gains Market Approval

Stock News15:24

HENGRUI PHARMA (01276) shares climbed more than 4% in late trading, currently up 3.9% to HK$58.6, with a trading volume of HK$220 million. On August 6, the company announced that the third indication for its Ruikang Trastuzumab Injection has received market approval, making it China's first anti-HER2 product approved for colorectal cancer. This indication targets adult patients with HER2-positive colorectal cancer who have failed treatment with oxaliplatin, fluorouracil, and irinotecan. Previously, the drug had been approved for two indications: non-small cell lung cancer and breast cancer.

Notably, in June this year, HENGRUI PHARMA's Cyclosporine Eye Drops IV (Hengyi) received approval for treating reduced tear production caused by dry eye disease. As China's first and only 0.1% anhydrous cyclosporine eye drop, this product offers multiple therapeutic advantages and is expected to drive clinical drug iteration. With several innovative products successively gaining market approval, the company's ophthalmology portfolio is entering a harvest phase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1177922465?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 15:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177922465","market":"us","top_or_hot":-1,"title":"HENGRUI PHARMA Shares Surge Over 4% in Late Trading as China's First Anti-HER2 Product for Colorectal Cancer Gains Market Approval","media":"Stock News","content":"<p><b>HENGRUI PHARMA (01276)</b> shares climbed more than 4% in late trading, currently up 3.9% to HK$58.6, with a trading volume of HK$220 million. On August 6, the company announced that the third indication for its Ruikang Trastuzumab Injection has received market approval, making it China's first anti-HER2 product approved for colorectal cancer. This indication targets adult patients with HER2-positive colorectal cancer who have failed treatment with oxaliplatin, fluorouracil, and irinotecan. Previously, the drug had been approved for two indications: non-small cell lung cancer and breast cancer.<br><br>Notably, in June this year, <b>HENGRUI PHARMA</b>'s Cyclosporine Eye Drops IV (Hengyi) received approval for treating reduced tear production caused by dry eye disease. As China's first and only 0.1% anhydrous cyclosporine eye drop, this product offers multiple therapeutic advantages and is expected to drive clinical drug iteration. With several innovative products successively gaining market approval, the company's ophthalmology portfolio is entering a harvest phase.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENGRUI PHARMA Shares Surge Over 4% in Late Trading as China's First Anti-HER2 Product for Colorectal Cancer Gains Market Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENGRUI PHARMA Shares Surge Over 4% in Late Trading as China's First Anti-HER2 Product for Colorectal Cancer Gains Market Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-07 15:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>HENGRUI PHARMA (01276)</b> shares climbed more than 4% in late trading, currently up 3.9% to HK$58.6, with a trading volume of HK$220 million. On August 6, the company announced that the third indication for its Ruikang Trastuzumab Injection has received market approval, making it China's first anti-HER2 product approved for colorectal cancer. This indication targets adult patients with HER2-positive colorectal cancer who have failed treatment with oxaliplatin, fluorouracil, and irinotecan. Previously, the drug had been approved for two indications: non-small cell lung cancer and breast cancer.<br><br>Notably, in June this year, <b>HENGRUI PHARMA</b>'s Cyclosporine Eye Drops IV (Hengyi) received approval for treating reduced tear production caused by dry eye disease. As China's first and only 0.1% anhydrous cyclosporine eye drop, this product offers multiple therapeutic advantages and is expected to drive clinical drug iteration. With several innovative products successively gaining market approval, the company's ophthalmology portfolio is entering a harvest phase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2289578879.USD","symbol_name":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","start_time":0,"source_url":"","article_id":"1177922465","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177922465","pubTimestamp":1786087459,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENGRUI PHARMA (01276) shares climbed more than 4% in late trading, currently up 3.9% to HK$58.6, with a trading volume of HK$220 million. On August 6, the company announced that the third indication...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","BK0060":"抗癌","LU0359201612.USD":"贝莱德中国基金A2","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1997245177.USD":"安联神洲A股基金","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","BK0196":"行业龙头","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","KCAI":"KraneShares China Alpha Index ETF","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","BK0239":"医药制造","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","IPOS":"Renaissance International IPO ETF","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","BK0183":"MSCI概念","LU1146622755.USD":"安本中国A股股票基金A Acc","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","BK4588":"碎股","BK0188":"融资融券","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK0012":"证金概念","01276":"恒瑞医药","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","VXUS":"国际股票ETF-Vanguard","BK0028":"国家队","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK1191":"制药","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H"},"translate_title":"中国首个治疗结直肠癌的抗HER2产品获得市场批准，恒瑞医药股价尾盘飙升逾4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1,"IPOS":1,"01276":1,"KCAI":1,"VXUS":1},"content_text":"HENGRUI PHARMA (01276) shares climbed more than 4% in late trading, currently up 3.9% to HK$58.6, with a trading volume of HK$220 million. On August 6, the company announced that the third indication for its Ruikang Trastuzumab Injection has received market approval, making it China's first anti-HER2 product approved for colorectal cancer. This indication targets adult patients with HER2-positive colorectal cancer who have failed treatment with oxaliplatin, fluorouracil, and irinotecan. Previously, the drug had been approved for two indications: non-small cell lung cancer and breast cancer.Notably, in June this year, HENGRUI PHARMA's Cyclosporine Eye Drops IV (Hengyi) received approval for treating reduced tear production caused by dry eye disease. As China's first and only 0.1% anhydrous cyclosporine eye drop, this product offers multiple therapeutic advantages and is expected to drive clinical drug iteration. With several innovative products successively gaining market approval, the company's ophthalmology portfolio is entering a harvest phase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177922465","isCrawlerRequest":true}